Study on the Efficacy and Safety of Ultrasound-Guided Peritendinous Injection of Low-Molecular-We… (NCT07699406) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Study on the Efficacy and Safety of Ultrasound-Guided Peritendinous Injection of Low-Molecular-Weight Hyaluronic Acid (Hyalotend®; 500-730 kDa) for Chronic Non-Calcific Supraspinatus Tendinopathy.
30 participantsStarted 2026-07
Plain-language summary
This study aims to evaluate whether ultrasound-guided injections of low-molecular-weight hyaluronic acid (Hyalotend®) can safely reduce pain and improve shoulder function in people with chronic non-calcific supraspinatus tendinopathy. Participants will receive two injections as part of their treatment and will be followed over time to assess changes in pain, shoulder function, medication use, treatment satisfaction, and any side effects. The information collected may help improve the treatment of this condition in future patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 years.
* Clinical and ultrasound-confirmed diagnosis of chronic (\>12 weeks) supraspinatus tendinopathy.
* No structural tendon tear, confirmed by ultrasound.
* No tendon calcification, confirmed by ultrasound.
* Previous failure of conservative treatment, including physical therapy and/or analgesic or anti-inflammatory medication.
* Written informed consent provided.
Exclusion Criteria:
* Partial- or full-thickness supraspinatus tendon tear identified by ultrasound.
* Calcific supraspinatus tendinopathy identified by ultrasound.
* Subacromial-subdeltoid bursitis identified by ultrasound
* Previous treatment with extracorporeal focus shock wave therapy within the last 3 months.
* Previous corticosteroid or platelet-rich plasma (PRP) injection within the last 3 months.
* History of hypersensitivity or allergy to hyaluronic acid or any of its components.
* Uncontrolled systemic disease.
* Other chronic rheumatologic or autoimmune diseases.
* Pregnancy or breastfeeding.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
QuickDASH questionary
Timeframe: 1. Before infiltrations 2. 4 weeks after second infiltration 3. 12 weeks after second infiltration
2
Constant-Murley questionary
Timeframe: 1. Before infiltrations 2. 4 weeks after second infiltration 3. 12 weeks after second infiltration
3
Visual Analog Scale
Timeframe: 1. Before infiltrations 2. 4 weeks after second infiltration 3. 12 weeks after second infiltration
Trial details
NCT IDNCT07699406
SponsorUniversity Hospital of the Nuestra Señora de Candelaria